Abstract: A process is disclosed for preparing a compound of the FormulaM (R.sup.1 R.sup.2 N.BH.sub.3)or a complex thereof of the FormulaM (R.sup.1 R.sup.2 N.BH.sub.3).xLwhereinM is Li, Na, K, Rb or Cs;R.sup.1 is H, an aliphatic C.sub.1 to C.sub.5 residue, an aromatic residue, or a cycloaliphatic residue;R.sup.2 is H, an aliphatic C.sub.1 to C.sub.5 residue, an aromatic residue, or a cycloaliphatic residue; orR.sup.1 and R.sup.2 form a common cyclic residue;L is a dipolar aprotic solvent; andx is a numerical value from 0.1 to 5, which comprises the steps of:(a) where the compound of the Formula M(R.sup.1 R.sup.2 N.BH.sub.3) is prepared, reacting a compound of the FormulaR.sup.1 R.sup.2 NH.BH.sub.3with an alkali metal or an alkali metal amide in a non-polar aliphatic or aromatic solvent; or(b) where the complex of the Formula M(R.sup.1 R.sup.2 N.BH.sub.3).xL is prepared, reacting the compound of the FormulaR.sup.1 R.sup.2 NH.BH.sub.

Abstract: 1. An optically active .beta.-aminoalkoxyborane complex of the formula (I): ##STR1## wherein R.sup.1 is C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.7 -C.sub.11 aralkyl or C.sub.6 -C.sub.10 aryl, R.sup.2 is hydrogen, C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.7 cycloalkyl or C.sub.7 -C.sub.11 aralkyl, or R.sub.1 and R.sup.2 together form (CH.sub.2).sub.n wherein n is 3 or 4, and Ar is naphthyl, anthryl or phenanthryl, which may be substituted by from 1 to 3 substituents selected from the group consisting of halogen, nitro, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, C.sub.7 -C.sub.11 aralkyl, C.sub.6 -C.sub.10 aryl, C.sub.1 -C.sub.6 alkoxy and styrene polymer substituents.

Abstract: Compounds are provided corresponding to the following general formula (I): in which:--R.sub.1 and R.sub.2, independently of each other, represent an alkyl group with 1 to 3 carbon atoms, or a group of formula --CH.sub.2 --OR.sub.a, R.sub.a representing a hydrogen atom or a methyl group R.sub.x represents: an alkyl group with 1 to 3 carbon atoms, in particular a methyl group, or an --OR.sub.x1 group, R.sub.x1 representing an alkyl group with 1 to 3 carbon atoms, in particular a methoxy group, or a group of formula --CH.sub.2 --X in which X represents a halogen atom, in particular chlorine, or a group of formula (a) ##STR1## in which: R.sub.3 and R.sub.5, independently of each other, represent a hydrogen atom, or an --OH group, or an --OCH.sub.3 group, R.sub.4 represents a hydrogen atom, or an --OR.sub.b group, R.sub.b representing a hydrogen atom or a methyl group, or R.sub.4 represents a group of formula --Or.sub.c, R.sub.c representing a group of formula --CH.sub.2 --CO--C.sub.6 H.sub.4 R'.

Abstract: Insecticidal substituted oxadiazines having the formula: ##STR1## wherein R is an optionally substituted C.sub.4 -C.sub.5 heterocyclic group and R' is hydrogen, halogen, C.sub.1 -C.sub.4 haloalkyl or C.sub.1 -C.sub.4 haloalkoxy,insecticidal compositions containing these oxadiazines, and methods for their use.

Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.

Abstract: Disclosed are photochromic oxazine compounds, yielded by means of condensation of an aldehyde bearing in the .alpha.-position to the aldehyde group a halogen or hydroxy group (reacting agent 1), with (substituted) ortho-aminohydroxy aromatic compounds (reacting agent 2).

Abstract: 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds, methods of preparing them and the use of these compounds in drugs are described.

Abstract: Antioxidant substances are obtained from vegetable matter by mixing vegetable matter containing antioxidant substances with a C.sub.2 -C.sub.6 alkylene glycol and subjecting the mixture to pressure of at least 40 bar to obtain a liquid extract. In carrying out the process, the vegetable matter mixed with the alkylene glycol has a moisture content of from 5% to 30% by weight. Further, to subject the mixture to pressure, the mixture is pressed, and additionally, the process includes filtering the extract to obtain a clear extract.

Abstract: Squarylium compounds of the formula: ##STR1## (in which Q.sup.1 and Q.sup.2 are each a chromophoric group having an aromatic unsaturated system conjugated with the squarylium ring and such that in the compounds of formulae Q.sup.1 CH.sub.2 R.sup.1 and Q.sup.2 CH.sub.2 R.sup.2 the methylene hydrogens are active hydrogens, R.sup.1 and R.sup.2 are each independently a hydrogen atom or an aliphatic or cycloaliphatic group, and R.sup.3 and R.sup.4 are each independently a hydrogen atom, or an acyl, aliphatic, cycloaliphatic, aromatic or heterocyclic group, subject to the proviso that one of R.sup.3 and R.sup.4 may be an amino or substituted amino group, or one of R.sup.3 and R.sup.4 is a hydrogen atom and the other is an organosulfonyl group, or R.sup.3 and R.sup.4 together with the intervening nitrogen atom form a nitrogenous heterocyclic ring) are useful as near infra-red absorbers.

Abstract: This invention relates to a method for inhibiting the growth of neoplasms, in a mammal having a prolactin profile. This method involves comparing the prolactin profile of the afflicted mammal to a standard prolactin profile for healthy mammals of the same species and sex and adjusting the prolactin profile of the afflicted mammal to conform to or approach the standard prolactin profile for a mammal of the same species and sex of the afflicted mammal, thereby inhibiting the neoplastic growth.

Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

Abstract: Biphenylylquinuclidine compounds of the formula I: ##STR1## and pharmaceutically-acceptable salts thereof; wherein R.sup.1 is hydrogen or hydroxy; R.sup.2 is hydrogen; or R.sup.1 and R.sup.2 are joined together so that CR.sup.1 -CR.sup.2 is a double bond; and one or both ring A and ring B may be optionally unsubstituted or independently substituted by one or more substituents selected from halogeno, hydroxy, amino, nitro, cyano, carboxy, carbamoyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylamino, di-?(1-6C)alkyl!amino, N-?(1-6C)alkyl!carbamoyl, N,N-di-?(1-6C)alkyl!carbamoyl, (1-6C)alkoxycarbonyl, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl and halogeno-(1-6C)alkyl; are inhibitors of squalene synthase and are hence useful in treating diseases or medical conditions such as hypercholesterolemia, atherosclerosis and fungal diseases.

Abstract: The invention provides dihydronaphthofluorene compounds, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, and cardiovascular-related pathological conditions.

Abstract: Disclosed is a benzoylethylene derivative represented by the following formula (I) or a salt thereof. ##STR1## R.sup.1 to R.sup.5 : a hydrogen atom, --OR.sup.9 (R.sup.9 : a hydrogen atom, a C.sub.1 -C.sub.5 alkyl group, etc.), etc.,R.sup.6 : a hydrogen atom, a C.sub.1 -C.sub.5 alkyl group, etc.,R.sup.7 : a hydrogen atom, a cyano group, a C.sub.1 -C.sub.5 alkyl group, --SO.sub.q R.sup.15 (q: 0, 1, 2, R.sup.15 : a thienyl group, a phenyl group, etc.) etc.,R.sup.8 : a cyano group, --CR.sup.22 R.sup.23 X (R.sup.22, R.sup.23 : a hydrogen atom, a C.sub.1 -C.sub.5 alkyl group, etc., X: --NR.sup.24 R.sup.25 (R.sup.24, R.sup.25 : a C.sub.1 -C.sub.5 alkyl group, etc., an alkylene group by combining, etc.)), etc.The benzoylethylene derivative of the present invention has potent tyrosine kinase inhibiting activity and cancer cell growth inhibiting activity. The tyrosine kinase inhibitor of the present invention is useful as a carcinostatic agent.

Abstract: The present invention provides an antibacterial and fungicidal agent containing an amino compound of formula (1) or a salt thereof. The invention also provides a method for imparting antibacterial and fungicidal properties to a variety of objects using the compound. ##STR1## wherein .phi. represents a phenyl group, a substituted phenyl group (wherein the substituents are 1-5 members arbitrarily selected from the group consisting of a hydroxyl group, halogen atoms, lower alkoxyl groups, trifluoromethyl group, an amino group, and a methylenedioxy group), or an imidazolyl group; R.sup.1 represents a hydrogen atom or a lower alkyl group; and R.sup.2 represents a C6-C12 alkyl group. The amino compound of formula (1) or a salt thereof exhibits excellent antibacterial effects and fungicidal effects, and when it is applied to a variety of articles used in industry, commodities, etc., enhanced antibacterial effects and fungicidal effects are obtained.

Abstract: A description is given of novel O-phenol-substituted aminophenol derivatives of the formula ##STR1## in which the symbols are as defined in claim 1, which can be used in particular as stabilizers for magenta couplers in color-photographic recording materials.

Abstract: Methods for treating prostate cancer are disclosed. The methods of the invention generally feature administration to a subject of an LHRH-R antagonist, in combination with a second therapy. In one embodiment, this second therapy is performance of a procedure that removes or destroys prostatic tumor tissue, such as a radical prostatectomy, cryosurgery or X-ray therapy (external or interstitial). In another embodiment, the second therapy is treatment with an LHRH-R agonist, either simultaneous with or subsequent to LHRH-R antagonist therapy. The methods of the invention can further involve administering an antiandrogen and/or an inhibitor of sex steroid biosynthesis to the subject in combination with the LHRH-R antagonist.

Abstract: A process for amidating a 2-azabicyclo?2.2.1!heptan-3-one or a 2-azabicyclo?2.2.1!hept-5-en-3-one by reaction with an amine, to form the corresponding ring-opened amide, is modified by the addition of an additive that accelerates the rate of reaction to an extent that the reaction can be carried out at atmospheric pressure.

Abstract: The present invention is directed to new cationic lipids and intermediates in their synthesis that are useful for transfecting nucleic acids or peptides into prokaryotic or eukaryotic cells. The lipids comprise one or two arginine, lysine or ornithine residues linked to a lipophilic moiety. The lipids form a composition when mixed with polyanions such as nucleic acids. The compositions permit efficient transfer of polyanions into cells without significant toxicity to the cells.

Abstract: Methods for cancer chemosensitization are provided. Texaphyrins are new chemosensitizers for enhancing the cytotoxicity of chemotherapeutic agents. The enhancement appears to be P-glycoprotein-independent since texaphyrins are effective in both a P-glycoprotein-expressing and a P-glycoprotein -nonexpressing cell line. Methods are provided for the treatment of cancers such as leukemia, lymphoma, carcinoma, and sarcoma using a texaphyrin as a chemosensitizer.